



Medicines & Healthcare products  
Regulatory Agency



Wynne Jones  
[cj-editor@biggeesblog.cymru](mailto:cj-editor@biggeesblog.cymru)

**MHRA**

10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[www.gov.uk/mhra](http://www.gov.uk/mhra)

5<sup>th</sup> May 2021

Dear Ms Jones

**Our Ref: FOI 21/347**

Thank you for your email dated 3<sup>rd</sup> April 2021, where you asked:

“Following the decision by Germany and Netherlands to restrict the use of the Covid 19 AstraZeneca vaccine in people under 60 years of age due to blood clotting concerns I would be pleased to receive the following information under the F O I Act 2000.

1. Copy of the latest version of MHRA "*Risk v Benefit analysis*" for Covid 19 AstraZeneca / Oxford vaccine, and
2. Copy of the latest version of MHRA "*Risk v Benefit analysis*" for Covid 19 Pfizer / BioNTech vaccine.”

In answer to your request, we would like to direct you to the weekly published summary of Yellow Card reporting for COVID-19 vaccines. This report summarises information received via the Yellow Card scheme and is updated regularly to include other safety investigations carried out by the MHRA under the [COVID-19 Vaccine Surveillance Strategy](#).  
<https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions>

You may also wish to read the latest statement from the JCVI on the use of the AstraZeneca COVID-19 vaccine: <https://www.gov.uk/government/news/new-jcvi-advice-on-use-of-the-astrazeneca-covid-19-vaccine>

I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team  
Vigilance and Risk Management of Medicines Division

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.



Medicines & Healthcare products  
Regulatory Agency



For information on the reproduction or re-use of MHRA information, please visit

<https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF

Copyright notice

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder.